Article (Scientific journals)
Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines
Colle, I.; Adler, M.; Brenard, R. et al.
2007In Acta Gastro-Enterologica Belgica, 70 (4), p. 389-420
Peer Reviewed verified by ORBi
 

Files


Full Text
Delwaide_2007_ActaGastroBel_389.pdf
Publisher postprint (3.24 MB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adenine/analogs & derivatives/therapeutic use; Antiviral Agents/therapeutic use; Drug Resistance, Viral; Guanine/analogs & derivatives/therapeutic use; HIV Infections/complications; Hepatitis B Vaccines; Hepatitis B e Antigens/analysis; Hepatitis B virus/immunology; Hepatitis B, Chronic/diagnosis/drug therapy/prevention & control/transmission; Hepatitis C, Chronic/complications; Humans; Interferon Alfa-2a/therapeutic use; Lamivudine/therapeutic use; Liver Cirrhosis/surgery/virology; Liver Transplantation; Mass Screening; Nucleosides/therapeutic use; Phosphonic Acids/therapeutic use; Polyethylene Glycols/therapeutic use; Pyrimidinones/therapeutic use; Reverse Transcriptase Inhibitors/therapeutic use; Vaccination
Abstract :
[en] 1. Introduction Chronic hepatitis B virus (HBV) infection currently affects about 400 million people and is responsible for 500,000 to 1,000,000 deaths annually worldwide from cirrhosis and hepatocellular carcinoma (HCC) (1). For this reason, screening high risk populations to identify HBV infected persons is important so that guidelines for treatment and prevention of transmission can be given in this specific group. Recently, new drugs became available for HBV and new insights in resistance and definitions came up. So, the purpose of this paper is providing an update of the recent literature and guidelines concerning 1. screening for chronic hepatitis B (CHB) 2. management of patients with CHB 3. treatment of CHB in mono-infected patients and in special patient populations (co-infected, transplanted and immunosuppressed patients). The recommendations are based onpublished information and the level of evidence is reported with each recommendation. The level of evidence is graded as :grade 1 : randomized controlled trials ; grade II-1 : controlled trials without randomization ; grade 11-2 : cohort or case-control analytic study ; grade 11-3 : multiple time series, dramatic uncontrolled experiments ; grade III : descriptive epidemiology, expert opinions.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Colle, I.
Adler, M.
Brenard, R.
Henrion, J.
Langlet, P.
Michielsen, P.
Orlent, H.
Reynaert, H.
Sprengers, D.
Starkel, P.
Van Damme, Pierre ;  Centre Hospitalier Universitaire de Liège - CHU > HOSPITALISATION - S.I. CHIRURGICAUX (SI +1D)
Verslype, C.
Delwaide, Jean ;  Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
More authors (3 more) Less
Language :
English
Title :
Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines
Publication date :
2007
Journal title :
Acta Gastro-Enterologica Belgica
ISSN :
0001-5644
eISSN :
1784-3227
Publisher :
Acta Medica Belgica, Bruxelles, Belgium
Volume :
70
Issue :
4
Pages :
389-420
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 28 September 2010

Statistics


Number of views
87 (0 by ULiège)
Number of downloads
2 (0 by ULiège)

Scopus citations®
 
11
Scopus citations®
without self-citations
7

Bibliography


Similar publications



Contact ORBi